

FOR IMMEDIATE RELEASE

ZODIAC ADVISES OF PRESENTATION AT 4TH SOUTH AFRICAN AIDS CONFERENCE

Sydney NSW, 29 March, 2009 -- Zodiac Capital Limited (NSX: ZOD) is pleased to advise a summary of the latest clinical study of Immunoxel in end-stage TB/HIV co-infection patients.

The clinical study which demonstrated a significant improvement in TB therapy outcome and a drastic reduction in the mortality rate of terminally-ill TB patients with HIV co-infection is being presented to delegates from all over the World at the 4th South African AIDS Conference being held in Durban from 31 March to 3 April 2009.

Advanced stage AIDS patients with pulmonary tuberculosis have very limited treatment options. For such patients treatment options are often limited to palliative care only.

In this latest clinical study 40 late-stage TB/HIV patients were treated over two months at the Lisichansk TB Dispensary in the Ukraine. The study was partly supported by a grant generously provided by the non profit MAPI Research Trust based in Lyon, France.

The botanical immunomodulator Immunoxel was administered along with TB drugs to 20 patients (Immunoxel group), while the other 20 received TB drugs only (Control group). Despite the best possible care six patients in the Immunoxel group died. The remaining 14 patients in the group experienced remarkable clinical improvements and one patient was discharged from the hospital due to full recovery within the 2 month therapy study time. Among 20 matched subjects on conventional TB drugs in the Control group, 12 died and only one patient showed any improvement at all. In this clinical study Immunoxel reduced the patient mortality rate by half and also significantly improved patient quality of life ($P=0.00002$).

Improvement in quality of life was also supported by substantial weight gain (mean/median 3.3/4.0 kg) in a much higher proportion of the Immunoxel group patients than among the Control group by a factor of 16:1 ($P=0.000001$). At the end of two months 13 (65%) patients treated with Immunoxel became sputum smear negative versus only one individual (5%) in Control group ($P=0.00007$). These results indicate that adjuvant Immunoxel immunotherapy significantly improves therapy outcome and reduces mortality.

Immunoxel is one of the 26 botanical phytopharmaceuticals that subject to shareholder approval the Company has agreed to joint venture with Stirling Products Limited as has previously been advised to the market on 25 March 2009.



CONTACT: For further detail or inquiry please contact:

Dr Allen Bain allen.bain@zodiaccap.com

Peter Squire peter.squire@zodiaccap.com

Zodiac Capital Limited

Level 1, 275 George Street

Sydney NSW 2000

Tel: +61(0)2 9299 9270

